How to Buy advenzymes Shares on Fincept?
You can buy Advanced Enzyme Technologies Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: Advanced Enzyme Technologies Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Advenzymes, including updates on board meetings and corporate actions.
Advanced Enzyme Technologies Limited - https://www.advancedenzymes.com
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers enzymes and probiotics-based nutritional supplements for human healthcare and animal nutrition, fruit and vegetable processing, baking, brewing and malting, starch and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as for specialty applications, biofuels, and bio-catalysis. It provides non-food processing enzymes for textile, leather, and pulp and paper processing, as well as detergents and cleaning aids. The company was formerly known as Advanced Biochemicals Limited and changed its name to Advanced Enzyme Technologies Limited in 2005. Advanced Enzyme Technologies Limited was founded in 1957 and is based in Thane, India.
Advanced Enzyme Technologies Limited Share Price Today
336.35
OPEN
339.85
HIGH
328.05
LOW
329.75
CLOSE
168 K
VOLUME
4,074 Cr
Market Cap
252470
Average Volume
Basic Materials
Sector
NSI
Exchange
Advanced Enzyme Technologies Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: ADVENZYMES Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
Advanced Enzyme Technologies Limited |
ADVENZYMES |
INE837H01012 |
Dividend - Re 1.1 Per Share |
18 Jul 2024 |
2 |
N/A |
Advanced Enzyme Technologies Limited |
ADVENZYMES |
INE837H01012 |
Interim Dividend - Rs 4 Per Share |
17 May 2024 |
2 |
N/A |
Advanced Enzyme Technologies Limited |
ADVENZYMES |
INE837H01012 |
Dividend - Re 1 Per Share |
04 Aug 2023 |
2 |
N/A |
Advanced Enzyme Technologies Limited |
ADVENZYMES |
INE837H01012 |
Interim Dividend - Rs 4 Per Share |
19 May 2023 |
2 |
N/A |
Advanced Enzyme Technologies Limited |
ADVENZYMES |
INE837H01012 |
Dividend - Re 1 Per Share |
11 Aug 2022 |
2 |
N/A |
NSE: ADVENZYMES Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
ADVENZYMES |
27 Dec 2024, 13:01:16 |
Trading Window |
N/A |
ADVENZYMES |
27 Dec 2024, 12:59:47 |
Trading Window-XBRL |
N/A |
ADVENZYMES |
19 Dec 2024, 16:25:50 |
Update-Acquisition/Scheme/Sale/Disposal-XBRL |
N/A |
ADVENZYMES |
19 Dec 2024, 15:55:42 |
General Updates |
N/A |
ADVENZYMES |
16 Dec 2024, 16:17:21 |
Analysts/Institutional Investor Meet/Con. Call Updates |
N/A |
NSE: ADVENZYMES Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
Advanced Enzyme Technologies Limited |
ADVENZYMES |
14 Oct 2024, 16:44:00 |
14 Oct 2024, 16:44:00 |
|
Advanced Enzyme Technologies Limited |
ADVENZYMES |
16 Jul 2024, 11:37:00 |
16 Jul 2024, 11:37:00 |
|
Advanced Enzyme Technologies Limited |
ADVENZYMES |
17 Apr 2024, 10:41:00 |
17 Apr 2024, 11:00:00 |
|
Advanced Enzyme Technologies Limited |
ADVENZYMES |
15 Jan 2024, 16:00:00 |
15 Jan 2024, 16:30:00 |
|
Advanced Enzyme Technologies Limited |
ADVENZYMES |
16 Oct 2023, 16:45:00 |
16 Oct 2023, 17:15:00 |
NSE: ADVENZYMES Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson Related To Promoters,Non-Executive Director |
17 Jan 1948 |
05 Mar 1993 |
01233447 |
Vasant L Rahi |
Active |
Independent Director |
06 Aug 1969 |
14 Dec 2016 |
00819790 |
Pramod Kasat |
Active |
Executive Director |
09 Jul 1972 |
04 Sep 1999 |
00148294 |
Mukund Madhusudan Kabra |
Active |
Non-Executive Director |
01 Dec 1982 |
08 Jan 2019 |
08300682 |
Rasika Rathi |
Active |
Independent Director |
21 Nov 1964 |
09 Feb 2019 |
08224980 |
Vinodkumar Hiralal Jajoo |
Active |
NSE: ADVENZYMES Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
Board Meeting Intimation |
ADVENZYMES |
N/A |
INE837H01012 |
Advanced Enzyme Technologies Limited |
30 Oct 2024, 18:09:53 |
ADVANCED ENZYME TECHNOLOGIES LIMITED has informed the Exchange about Board Meeting to be held on 10-Aug-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended June 2024 . |
ADVENZYMES |
N/A |
INE837H01012 |
Advanced Enzyme Technologies Limited |
02 Aug 2024, 14:52:32 |
ADVANCED ENZYME TECHNOLOGIES LIMITED has informed the Exchange about Board Meeting to be held on 11-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Dividend. |
ADVENZYMES |
N/A |
INE837H01012 |
Advanced Enzyme Technologies Limited |
04 May 2024, 19:09:40 |
ADVANCED ENZYME TECHNOLOGIES LIMITED has informed the Exchange about Board Meeting to be held on 10-Feb-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended December 2023 . |
ADVENZYMES |
N/A |
INE837H01012 |
Advanced Enzyme Technologies Limited |
03 Feb 2024, 17:58:02 |
Financial Results |
ADVENZYMES |
N/A |
INE837H01012 |
Advanced Enzyme Technologies Limited |
31 Oct 2023, 17:50:11 |
NSE: ADVENZYMES Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results |
ADVENZYMES |
- |
INE837H01012 |
Advanced Enzyme Technologies Limited |
30 Oct 2024, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2024 |
Financial Results |
ADVENZYMES |
- |
INE837H01012 |
Advanced Enzyme Technologies Limited |
02 Aug 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024 |
Financial Results/Dividend |
ADVENZYMES |
- |
INE837H01012 |
Advanced Enzyme Technologies Limited |
04 May 2024, 00:00:00 |
This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Saturday, May 11, 2024, inter alia, to consider the following:To consider & approve annual Financial Statements (Standalone & Consolidated) of the Company for the financial year ended March 31, 2024 along with results of the fourth quarter;To consider & recommend Final dividend, if any, for the financial year ended March 31, 2024, and/or to consider & declare Interim Dividend, if any for the financial year ended March 31, 2025.The Record date for determining the shareholders for the payment of the aforesaid Interim Dividend for FY2024-25, if any declared by the Board of Directors of the Company shall be Saturday, May 18, 2024.Closure of Trading Window:Further to our letter dated March 29, 2024 intimating closure of Trading Window, we wish to inform you that the Trading Window for dealing in the Securities of the Company will continue to remain closed up to May 13, 2024. |
Financial Results |
ADVENZYMES |
- |
INE837H01012 |
Advanced Enzyme Technologies Limited |
03 Feb 2024, 00:00:00 |
Advanced Enzyme Technologies Ltdhas informed NSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 ,inter alia, to consider and approve Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2023. |
Financial Results |
ADVENZYMES |
- |
INE837H01012 |
Advanced Enzyme Technologies Limited |
31 Oct 2023, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2023 |
NSE: ADVENZYMES Balance Sheet Data In (Cr)
| date | period_type | Treasury Shares Number | Ordinary Shares Number | Share Issued | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Capital Lease Obligations | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Minority Interest | Stockholders Equity | Other Equity Interest | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Other Non Current Liabilities | Liabilities Heldfor Sale Non Current | Non Current Pension And Other Postretirement Benefit Plans | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Deferred Taxes Liabilities | Current Debt And Capital Lease Obligation | Current Capital Lease Obligation | Current Debt | Pensionand Other Post Retirement Benefit Plans Current | Current Provisions | Payables | Other Payable | Dividends Payable | Total Tax Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Non Current Prepaid Assets | Non Current Deferred Taxes Assets | Investmentin Financial Assets | Available For Sale Securities | Financial Assets Designatedas Fair Value Through Profitor Loss | Goodwill And Other Intangible Assets | Other Intangible Assets | Goodwill | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Restricted Cash | Prepaid Assets | Inventory | Finished Goods | Work In Process | Raw Materials | Other Receivables | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 0.00 | 111,824,075.00 | 111,824,075.00 | 469,180,000.00 | 9,575,360,000.00 | 13,673,430,000.00 | 7,014,410,000.00 | 9,575,360,000.00 | 212,290,000.00 | 13,416,540,000.00 | 13,483,360,000.00 | 13,887,850,000.00 | 471,310,000.00 | 13,416,540,000.00 | 13,192,890,000.00 | 0.00 | 0.00 | 223,650,000.00 | 223,650,000.00 | 1,603,960,000.00 | 564,440,000.00 | 0.00 | 0.00 | 0.00 | 339,280,000.00 | 213,720,000.00 | 146,900,000.00 | 66,820,000.00 | 11,440,000.00 | 1,039,520,000.00 | 145,110,000.00 | 0.00 | 255,460,000.00 | 65,390,000.00 | 190,070,000.00 | 0.00 | 186,090,000.00 | 231,120,000.00 | 0.00 | 0.00 | 5,860,000.00 | 225,260,000.00 | 15,491,810,000.00 | 7,437,880,000.00 | 28,840,000.00 | 0.00 | 130,790,000.00 | 45,200,000.00 | 45,200,000.00 | 0.00 | 3,841,180,000.00 | 563,670,000.00 | 3,277,510,000.00 | 3,150,280,000.00 | 0.00 | 3,150,280,000.00 | 338,780,000.00 | 2,811,500,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8,053,930,000.00 | 156,480,000.00 | 0.00 | 0.00 | 1,684,100,000.00 | 0.00 | 0.00 | 0.00 | 1,210,000.00 | 987,580,000.00 | 0.00 | 0.00 | 5,224,560,000.00 | 4,246,730,000.00 | 977,830,000.00 | 0.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 0.00 | 111,824,075.00 | 111,824,075.00 | 473,080,000.00 | 9,405,470,000.00 | 13,492,400,000.00 | 7,031,140,000.00 | 9,405,470,000.00 | 221,960,000.00 | 13,241,280,000.00 | 13,310,880,000.00 | 13,710,800,000.00 | 469,520,000.00 | 13,241,280,000.00 | 30,310,000.00 | 10,794,910,000.00 | 821,310,000.00 | 223,650,000.00 | 223,650,000.00 | 1,643,830,000.00 | 580,260,000.00 | 0.00 | 0.00 | 8,860,000.00 | 343,240,000.00 | 228,160,000.00 | 158,560,000.00 | 69,600,000.00 | 8,860,000.00 | 1,063,570,000.00 | 135,910,000.00 | 0.00 | 244,920,000.00 | 63,400,000.00 | 181,520,000.00 | 0.00 | 196,750,000.00 | 524,610,000.00 | 274,020,000.00 | 1,590,000.00 | 91,410,000.00 | 157,590,000.00 | 15,354,630,000.00 | 7,259,930,000.00 | 300,000.00 | 80,230,000.00 | 142,820,000.00 | 1,710,000.00 | 60,000.00 | 1,650,000.00 | 3,835,810,000.00 | 582,860,000.00 | 3,252,950,000.00 | 3,072,660,000.00 | -1,880,840,000.00 | 4,953,500,000.00 | 307,370,000.00 | 2,765,280,000.00 | 2,665,830,000.00 | 1,399,320,000.00 | 580,980,000.00 | 0.00 | 8,094,710,000.00 | 17,260,000.00 | 2,260,000.00 | 111,040,000.00 | 1,484,550,000.00 | 357,870,000.00 | 363,410,000.00 | 763,270,000.00 | 14,200,000.00 | 985,680,000.00 | -12,360,000.00 | 998,040,000.00 | 5,479,720,000.00 | 4,342,210,000.00 | 1,137,510,000.00 | 717,480,000.00 | 420,030,000.00 |
| 2024-03-31T00:00:00 | annual | 0.00 | 111,824,075.00 | 111,824,075.00 | 473,080,000.00 | 9,405,470,000.00 | 13,492,400,000.00 | 7,031,140,000.00 | 9,405,470,000.00 | 221,960,000.00 | 13,241,280,000.00 | 13,310,880,000.00 | 13,710,800,000.00 | 469,520,000.00 | 13,241,280,000.00 | 30,310,000.00 | 10,794,910,000.00 | 821,310,000.00 | 223,650,000.00 | 223,650,000.00 | 1,643,830,000.00 | 580,260,000.00 | 0.00 | 0.00 | 8,860,000.00 | 343,240,000.00 | 228,160,000.00 | 158,560,000.00 | 69,600,000.00 | 8,860,000.00 | 1,063,570,000.00 | 135,910,000.00 | 0.00 | 244,920,000.00 | 63,400,000.00 | 181,520,000.00 | 0.00 | 196,750,000.00 | 524,610,000.00 | 274,020,000.00 | 1,590,000.00 | 91,410,000.00 | 157,590,000.00 | 15,354,630,000.00 | 7,259,930,000.00 | 300,000.00 | 80,230,000.00 | 142,820,000.00 | 1,710,000.00 | 60,000.00 | 1,650,000.00 | 3,835,810,000.00 | 582,860,000.00 | 3,252,950,000.00 | 3,072,660,000.00 | -1,880,840,000.00 | 4,953,500,000.00 | 307,370,000.00 | 2,765,280,000.00 | 2,665,830,000.00 | 1,399,320,000.00 | 580,980,000.00 | 0.00 | 8,094,710,000.00 | 17,260,000.00 | 2,260,000.00 | 111,040,000.00 | 1,484,550,000.00 | 357,870,000.00 | 363,410,000.00 | 763,270,000.00 | 14,200,000.00 | 985,680,000.00 | -12,360,000.00 | 998,040,000.00 | 5,479,720,000.00 | 4,342,210,000.00 | 1,137,510,000.00 | 717,480,000.00 | 420,030,000.00 |
| 2023-09-30T00:00:00 | quarterly | 0.00 | 111,824,075.00 | 111,824,075.00 | 388,610,000.00 | 8,681,650,000.00 | 12,689,860,000.00 | 6,483,210,000.00 | 8,681,650,000.00 | 181,570,000.00 | 12,482,820,000.00 | 12,556,940,000.00 | 12,987,350,000.00 | 504,530,000.00 | 12,482,820,000.00 | 12,259,170,000.00 | 0.00 | 0.00 | 223,650,000.00 | 223,650,000.00 | 1,451,810,000.00 | 577,820,000.00 | 0.00 | 0.00 | 0.00 | 357,210,000.00 | 214,790,000.00 | 140,670,000.00 | 74,120,000.00 | 5,820,000.00 | 873,990,000.00 | 96,660,000.00 | 0.00 | 173,820,000.00 | 40,900,000.00 | 132,920,000.00 | 0.00 | 27,240,000.00 | 296,130,000.00 | 0.00 | 0.00 | 33,230,000.00 | 262,900,000.00 | 14,439,160,000.00 | 7,081,960,000.00 | 31,100,000.00 | 0.00 | 113,680,000.00 | 46,760,000.00 | 46,760,000.00 | 0.00 | 3,801,170,000.00 | 566,150,000.00 | 3,235,020,000.00 | 2,899,050,000.00 | 0.00 | 2,899,050,000.00 | 165,430,000.00 | 2,733,620,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7,357,200,000.00 | 165,300,000.00 | 0.00 | 0.00 | 1,356,250,000.00 | 0.00 | 0.00 | 0.00 | 1,380,000.00 | 1,119,990,000.00 | 0.00 | 0.00 | 4,714,280,000.00 | 3,714,870,000.00 | 999,410,000.00 | 0.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 0.00 | 111,824,075.00 | 111,824,075.00 | 334,990,000.00 | 8,533,380,000.00 | 12,483,080,000.00 | 6,434,900,000.00 | 8,533,380,000.00 | 202,600,000.00 | 12,350,690,000.00 | 12,428,680,000.00 | 12,841,710,000.00 | 491,020,000.00 | 12,350,690,000.00 | 12,127,040,000.00 | 10,022,770,000.00 | 821,310,000.00 | 223,650,000.00 | 223,650,000.00 | 1,376,760,000.00 | 601,100,000.00 | 0.00 | 0.00 | 5,060,000.00 | 372,270,000.00 | 223,770,000.00 | 145,780,000.00 | 77,990,000.00 | 5,060,000.00 | 775,660,000.00 | 105,220,000.00 | 0.00 | 111,220,000.00 | 56,820,000.00 | 54,400,000.00 | 0.00 | 37,190,000.00 | 550,850,000.00 | 292,630,000.00 | 1,170,000.00 | 14,840,000.00 | 242,210,000.00 | 14,218,470,000.00 | 7,007,910,000.00 | 850,000.00 | 62,410,000.00 | 113,420,000.00 | 1,700,000.00 | 50,000.00 | 1,650,000.00 | 3,817,310,000.00 | 608,780,000.00 | 3,208,530,000.00 | 2,888,220,000.00 | -1,620,480,000.00 | 4,508,700,000.00 | 156,090,000.00 | 2,732,130,000.00 | 2,500,370,000.00 | 1,280,500,000.00 | 571,740,000.00 | 0.00 | 7,210,560,000.00 | 9,680,000.00 | 5,920,000.00 | 98,160,000.00 | 1,239,900,000.00 | 286,530,000.00 | 325,840,000.00 | 627,530,000.00 | 10,680,000.00 | 1,003,410,000.00 | -15,470,000.00 | 1,018,880,000.00 | 4,842,810,000.00 | 3,878,610,000.00 | 964,200,000.00 | 363,680,000.00 | 600,520,000.00 |
| 2023-03-31T00:00:00 | annual | 0.00 | 111,824,075.00 | 111,824,075.00 | 334,990,000.00 | 8,533,380,000.00 | 12,483,080,000.00 | 6,434,900,000.00 | 8,533,380,000.00 | 202,600,000.00 | 12,350,690,000.00 | 12,428,680,000.00 | 12,841,710,000.00 | 491,020,000.00 | 12,350,690,000.00 | 12,127,040,000.00 | 10,022,770,000.00 | 821,310,000.00 | 223,650,000.00 | 223,650,000.00 | 1,376,760,000.00 | 601,100,000.00 | 0.00 | 0.00 | 5,060,000.00 | 372,270,000.00 | 223,770,000.00 | 145,780,000.00 | 77,990,000.00 | 5,060,000.00 | 775,660,000.00 | 105,220,000.00 | 0.00 | 111,220,000.00 | 56,820,000.00 | 54,400,000.00 | 0.00 | 37,190,000.00 | 550,850,000.00 | 292,630,000.00 | 1,170,000.00 | 14,840,000.00 | 242,210,000.00 | 14,218,470,000.00 | 7,007,910,000.00 | 850,000.00 | 62,410,000.00 | 113,420,000.00 | 1,700,000.00 | 50,000.00 | 1,650,000.00 | 3,817,310,000.00 | 608,780,000.00 | 3,208,530,000.00 | 2,888,220,000.00 | -1,620,480,000.00 | 4,508,700,000.00 | 156,090,000.00 | 2,732,130,000.00 | 2,500,370,000.00 | 1,280,500,000.00 | 571,740,000.00 | 0.00 | 7,210,560,000.00 | 9,680,000.00 | 5,920,000.00 | 98,160,000.00 | 1,239,900,000.00 | 286,530,000.00 | 325,840,000.00 | 627,530,000.00 | 10,680,000.00 | 1,003,410,000.00 | -15,470,000.00 | 1,018,880,000.00 | 4,842,810,000.00 | 3,878,610,000.00 | 964,200,000.00 | 363,680,000.00 | 600,520,000.00 |
| 2022-03-31T00:00:00 | annual | 0.00 | 111,800,675.00 | 111,800,675.00 | 347,300,000.00 | 7,262,240,000.00 | 10,995,330,000.00 | 5,399,320,000.00 | 7,262,240,000.00 | 237,900,000.00 | 10,885,930,000.00 | 10,967,230,000.00 | 11,403,860,000.00 | 517,930,000.00 | 10,885,930,000.00 | 6,400,000.00 | 9,072,970,000.00 | 813,550,000.00 | 223,600,000.00 | 223,600,000.00 | 1,272,230,000.00 | 668,010,000.00 | 0.00 | 0.00 | 10,680,000.00 | 392,500,000.00 | 264,830,000.00 | 183,530,000.00 | 81,300,000.00 | 10,680,000.00 | 604,220,000.00 | 97,750,000.00 | 0.00 | 82,470,000.00 | 54,370,000.00 | 28,100,000.00 | 0.00 | 38,220,000.00 | 414,200,000.00 | 232,160,000.00 | 1,080,000.00 | 1,990,000.00 | 178,970,000.00 | 12,676,090,000.00 | 6,672,550,000.00 | 840,000.00 | 81,280,000.00 | 74,200,000.00 | 700,000.00 | 50,000.00 | 650,000.00 | 3,623,690,000.00 | 663,060,000.00 | 2,960,630,000.00 | 2,718,080,000.00 | -1,374,110,000.00 | 4,092,190,000.00 | 96,280,000.00 | 2,621,800,000.00 | 2,341,960,000.00 | 1,123,940,000.00 | 530,010,000.00 | 0.00 | 6,003,540,000.00 | 4,730,000.00 | 44,770,000.00 | 98,970,000.00 | 1,209,200,000.00 | 347,250,000.00 | 303,540,000.00 | 558,410,000.00 | 26,410,000.00 | 882,060,000.00 | -8,480,000.00 | 890,540,000.00 | 3,737,400,000.00 | 1,063,850,000.00 | 2,673,550,000.00 | 819,940,000.00 | 1,853,610,000.00 |
| 2021-03-31T00:00:00 | annual | 0.00 | 111,728,425.00 | 111,728,425.00 | 279,630,000.00 | 6,075,450,000.00 | 9,900,050,000.00 | 4,484,580,000.00 | 6,075,450,000.00 | 88,980,000.00 | 9,709,400,000.00 | 9,808,110,000.00 | 10,326,220,000.00 | 616,820,000.00 | 9,709,400,000.00 | 26,200,000.00 | 7,977,310,000.00 | 789,560,000.00 | 223,460,000.00 | 223,460,000.00 | 1,235,510,000.00 | 559,950,000.00 | -10,000.00 | 0.00 | 13,560,000.00 | 408,500,000.00 | 137,890,000.00 | 39,180,000.00 | 98,710,000.00 | 13,560,000.00 | 675,560,000.00 | 130,070,000.00 | 5,390,000.00 | 141,740,000.00 | 49,800,000.00 | 91,940,000.00 | 0.00 | 40,430,000.00 | 391,710,000.00 | 236,730,000.00 | 920,000.00 | 1,890,000.00 | 152,170,000.00 | 11,561,730,000.00 | 6,401,590,000.00 | 520,000.00 | 67,660,000.00 | 68,680,000.00 | 700,000.00 | 50,000.00 | 650,000.00 | 3,633,950,000.00 | 746,740,000.00 | 2,887,210,000.00 | 2,510,300,000.00 | -1,107,070,000.00 | 3,617,370,000.00 | 48,620,000.00 | 183,460,000.00 | 2,164,880,000.00 | 873,860,000.00 | 530,010,000.00 | 0.00 | 5,160,140,000.00 | 3,980,000.00 | 3,650,000.00 | 95,240,000.00 | 938,810,000.00 | 232,520,000.00 | 212,240,000.00 | 494,050,000.00 | 33,850,000.00 | 862,740,000.00 | -7,280,000.00 | 870,020,000.00 | 3,221,870,000.00 | 1,302,680,000.00 | 1,919,190,000.00 | 738,720,000.00 | 1,180,470,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 54,760,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7,790,000.00 | 0.00 | 0.00 | 0.00 | 32,290,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: ADVENZYMES Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Repayment Of Debt | Issuance Of Debt | Issuance Of Capital Stock | Capital Expenditure | End Cash Position | Other Cash Adjustment Outside Changein Cash | Beginning Cash Position | Effect Of Exchange Rate Changes | Changes In Cash | Financing Cash Flow | Net Other Financing Charges | Interest Paid Cff | Cash Dividends Paid | Common Stock Dividend Paid | Net Common Stock Issuance | Common Stock Issuance | Net Issuance Payments Of Debt | Net Short Term Debt Issuance | Short Term Debt Payments | Short Term Debt Issuance | Net Long Term Debt Issuance | Long Term Debt Payments | Long Term Debt Issuance | Investing Cash Flow | Net Other Investing Changes | Interest Received Cfi | Net Investment Purchase And Sale | Sale Of Investment | Purchase Of Investment | Net Business Purchase And Sale | Purchase Of Business | Net Intangibles Purchase And Sale | Sale Of Intangibles | Purchase Of Intangibles | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Capital Expenditure Reported | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Other Current Liabilities | Change In Other Current Assets | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Stock Based Compensation | Provisionand Write Offof Assets | Depreciation And Amortization | Amortization Cash Flow | Depreciation | Gain Loss On Investment Securities | Net Foreign Currency Exchange Gain Loss | Gain Loss On Sale Of PPE | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 940,560,000.00 | -6,480,000.00 | 127,030,000.00 | 0.00 | -473,130,000.00 | 1,137,510,000.00 | 0.00 | 964,200,000.00 | -1,510,000.00 | 174,820,000.00 | -592,380,000.00 | -56,070,000.00 | -29,250,000.00 | -567,120,000.00 | -567,120,000.00 | 0.00 | 0.00 | 120,550,000.00 | 127,030,000.00 | 0.00 | 127,030,000.00 | -6,480,000.00 | -6,480,000.00 | 0.00 | -646,490,000.00 | 0.00 | 129,390,000.00 | -304,300,000.00 | 0.00 | -304,300,000.00 | 0.00 | 0.00 | -500,000.00 | 0.00 | -500,000.00 | -421,580,000.00 | 1,550,000.00 | -423,130,000.00 | -49,500,000.00 | 1,413,690,000.00 | -492,340,000.00 | -262,530,000.00 | -1,280,000.00 | -31,440,000.00 | -39,410,000.00 | -238,340,000.00 | 7,730,000.00 | -100,260,000.00 | 30,310,000.00 | 105,700,000.00 | 352,420,000.00 | 77,400,000.00 | 275,020,000.00 | -108,480,000.00 | -820,000.00 | 2,300,000.00 | 1,878,210,000.00 |
| 2023-03-31T00:00:00 | annual | 1,021,810,000.00 | -3,220,000.00 | 26,220,000.00 | 1,420,000.00 | -381,810,000.00 | 964,200,000.00 | 200,000.00 | 2,673,550,000.00 | 126,620,000.00 | -1,836,170,000.00 | -257,980,000.00 | -68,000,000.00 | -24,210,000.00 | -125,420,000.00 | -125,420,000.00 | 1,420,000.00 | 1,420,000.00 | 23,000,000.00 | 26,220,000.00 | 0.00 | 26,220,000.00 | -3,220,000.00 | -3,220,000.00 | 0.00 | -2,981,810,000.00 | 500,000.00 | 78,700,000.00 | -2,681,740,000.00 | 0.00 | -2,681,740,000.00 | 0.00 | 0.00 | -760,000.00 | 0.00 | -760,000.00 | -378,510,000.00 | 2,540,000.00 | -381,050,000.00 | 0.00 | 1,403,620,000.00 | -366,390,000.00 | -3,410,000.00 | 22,860,000.00 | 15,460,000.00 | 60,280,000.00 | 7,550,000.00 | -101,340,000.00 | -21,140,000.00 | 0.00 | 4,200,000.00 | 350,290,000.00 | 73,040,000.00 | 277,250,000.00 | 21,980,000.00 | -1,070,000.00 | 7,990,000.00 | 1,403,880,000.00 |
| 2022-03-31T00:00:00 | annual | 941,150,000.00 | -23,200,000.00 | 6,740,000.00 | 4,340,000.00 | -281,760,000.00 | 2,673,550,000.00 | 0.00 | 1,919,190,000.00 | 54,320,000.00 | 700,040,000.00 | -485,000,000.00 | -211,250,000.00 | -17,760,000.00 | -118,600,000.00 | -118,600,000.00 | 4,340,000.00 | 4,340,000.00 | -81,380,000.00 | -64,920,000.00 | -64,920,000.00 | 0.00 | -16,460,000.00 | -23,200,000.00 | 6,740,000.00 | -37,870,000.00 | 0.00 | 12,280,000.00 | 218,600,000.00 | 220,990,000.00 | -2,390,000.00 | 0.00 | 0.00 | -600,000.00 | 0.00 | -600,000.00 | -268,150,000.00 | 13,010,000.00 | -281,160,000.00 | 0.00 | 1,222,910,000.00 | -545,310,000.00 | -273,990,000.00 | -28,300,000.00 | 6,680,000.00 | 27,980,000.00 | -260,950,000.00 | -14,030,000.00 | 7,200,000.00 | 0.00 | -9,930,000.00 | 349,830,000.00 | 79,980,000.00 | 269,850,000.00 | -3,250,000.00 | -80,000.00 | -11,500,000.00 | 1,710,580,000.00 |
| 2021-03-31T00:00:00 | annual | 1,433,870,000.00 | -236,890,000.00 | 120,030,000.00 | 3,000,000.00 | -195,800,000.00 | 1,919,190,000.00 | 6,020,000.00 | 826,640,000.00 | -18,960,000.00 | 1,105,490,000.00 | -263,850,000.00 | 39,830,000.00 | -15,360,000.00 | -79,810,000.00 | -79,810,000.00 | 3,000,000.00 | 3,000,000.00 | -116,860,000.00 | -71,700,000.00 | -111,530,000.00 | 39,830,000.00 | -45,160,000.00 | -125,360,000.00 | 80,200,000.00 | -260,330,000.00 | 0.00 | 9,100,000.00 | -58,880,000.00 | 0.00 | -58,880,000.00 | -16,260,000.00 | -16,260,000.00 | -1,330,000.00 | 0.00 | -1,330,000.00 | -192,960,000.00 | 1,510,000.00 | -194,470,000.00 | 0.00 | 1,629,670,000.00 | -567,100,000.00 | -150,280,000.00 | -16,770,000.00 | 16,030,000.00 | 14,730,000.00 | -81,800,000.00 | -72,730,000.00 | -33,680,000.00 | 3,810,000.00 | -4,550,000.00 | 287,220,000.00 | 64,120,000.00 | 223,100,000.00 | -1,550,000.00 | 910,000.00 | -7,250,000.00 | 2,101,320,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -112,970,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,780,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | -506,510,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: ADVENZYMES Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Minority Interests | Net Income Including Noncontrolling Interests | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Write Off | Impairment Of Capital Assets | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Amortization | Depreciation Income Statement | Research And Development | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Rent And Landing Fees | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | -2.42 | 0.00 | 234.91 | -8.92 | -8.92 | 133.31 | 35.24 | 159.41 | 225.99 | 190.75 | 9.21 | 2.93 | 13.33 | 139.81 | 133.31 | 450.65 | 7.95 | 11.19 | 11.18 | 0.00 | 0.00 | 133.31 | 133.31 | 0.00 | 133.31 | -3.65 | 136.95 | 136.95 | 50.87 | 187.82 | 14.16 | -17.53 | 15.44 | 2.10 | 0.00 | 9.21 | 1.19 | 2.93 | 13.33 | 172.83 | 291.24 | 79.36 | 35.24 | 7.74 | 27.50 | 0.81 | 39.72 | 15.65 | 24.07 | 7.95 | 464.07 | 159.41 | 623.48 | 623.48 |
| 2023-03-31T00:00:00 | annual | -2.38 | 0.00 | 186.99 | -9.16 | -9.16 | 105.64 | 35.03 | 142.77 | 177.84 | 142.81 | 6.01 | 2.42 | 9.48 | 112.41 | 105.64 | 402.09 | 6.24 | 11.18 | 11.18 | 0.00 | 0.00 | 105.64 | 105.64 | 0.00 | 105.64 | 1.77 | 103.87 | 103.87 | 36.52 | 140.39 | 3.94 | -6.43 | 4.81 | 0.93 | 0.69 | 6.01 | 1.06 | 2.42 | 9.48 | 138.30 | 259.32 | 75.24 | 35.03 | 7.30 | 27.73 | 0.81 | 37.91 | 16.08 | 21.83 | 6.24 | 397.61 | 142.77 | 540.38 | 540.38 |
| 2022-03-31T00:00:00 | annual | 0.06 | 0.00 | 207.61 | 0.23 | 0.23 | 119.58 | 34.98 | 119.43 | 207.84 | 172.85 | -2.55 | 1.80 | 0.40 | 119.42 | 119.58 | 360.34 | 4.24 | 11.19 | 11.18 | 0.00 | 0.00 | 119.58 | 119.58 | 0.00 | 119.58 | -4.22 | 123.80 | 123.80 | 47.26 | 171.06 | 4.57 | 0.23 | -1.15 | 0.92 | 0.00 | -2.55 | 1.16 | 1.80 | 0.40 | 168.57 | 240.91 | 61.90 | 34.98 | 8.00 | 26.99 | 0.65 | 35.49 | 14.77 | 20.72 | 4.24 | 409.47 | 119.43 | 528.90 | 528.90 |
| 2021-03-31T00:00:00 | annual | -0.06 | 0.00 | 240.67 | -0.21 | -0.21 | 145.93 | 28.72 | 105.59 | 240.46 | 211.74 | -1.99 | 1.61 | 0.59 | 146.08 | 145.93 | 290.94 | 2.10 | 11.19 | 11.17 | 0.00 | 0.00 | 145.93 | 145.93 | 0.00 | 145.93 | -5.36 | 151.29 | 151.29 | 58.85 | 210.13 | 2.98 | -0.21 | -0.73 | 0.93 | 0.00 | -1.99 | 0.96 | 1.61 | 0.59 | 209.51 | 185.35 | 47.58 | 28.72 | 6.41 | 22.31 | 0.63 | 24.38 | 8.55 | 15.83 | 2.10 | 394.85 | 105.59 | 500.45 | 500.45 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
5/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
12.24
P/E
29.746733
P/B
3.0307066
Dividend Yield
1.41%
Market Cap
4,073.59 Cr.
Face Value
120.137
Book Value
120.137
ROE
22.13%
EBITDA Growth
193.03 Cr.
Debt/Equity
3.378
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of advenzymes?
The market capitalization of Advanced Enzyme Technologies Limited is ₹4,074 Cr as of 05 Feb 2025.
What are the PE and PB ratios of Advanced Enzyme Technologies Limited?
The PE and PB ratios of Advanced Enzyme Technologies Limited are Not Available and 3.0307066 respectively as of 05 Feb 2025.
What is the 52 Week High of Advanced Enzyme Technologies Limited?
The 52-week high of Advanced Enzyme Technologies Limited is ₹571 as of 05 Feb 2025.
What is the 52 Week Low of Advanced Enzyme Technologies Limited?
The 52-week low of Advanced Enzyme Technologies Limited is ₹334.05 as of 05 Feb 2025.
What are the earnings per share (EPS) for Advanced Enzyme Technologies Limited?
The Earnings Per Share (EPS) of Advanced Enzyme Technologies Limited is ₹12.24 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of Advanced Enzyme Technologies Limited?
The Return on Equity (ROE) of Advanced Enzyme Technologies Limited is 22.13% as per the most recent financial year data. Explore more on Fincept.